TABLE I.
Baseline characteristics of the oncology drug review process
| Variable | Value |
|---|---|
| Distinct drugs (chemical entities) reviewed (n) | 51 |
| Indications receiving a NOC (n) | 88 |
| Route of administration | |
| Oral | 44 |
| Intravenous | 35 |
| Intramuscular | 1 |
| Subcutaneous | 8 |
| Submission period | |
| Pre-pCODR | 52 |
| pCODR | 36 |
| NOC date | |
| 2003–2005 | 8 |
| 2006–2008 | 23 |
| 2009–2011 | 25 |
| 2012–2014 | 32 |
| Tumour group | |
| Hematologic | 28 |
| Gastrointestinal | 12 |
| Lung | 12 |
| Renal | 9 |
| Breast | 8 |
| Prostatic | 6 |
| Dermatologic | 5 |
| Sarcoma | 4 |
| Thyroid | 1 |
| Ovarian | 1 |
| Head and neck | 1 |
| Central nervous system | 1 |
NOC = Notice of Compliance; pCODR = pan-Canadian Oncology Drug Review.